U.S. markets closed

Ambu A/S (AMBBY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
49.68-0.24 (-0.49%)
At close: 2:27PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close49.92
Open49.68
Bid0.00 x 0
Ask0.00 x 0
Day's Range49.68 - 49.68
52 Week Range39.02 - 52.99
Volume802
Avg. Volume1,852
Market Cap12.814B
Beta (5Y Monthly)0.27
PE Ratio (TTM)265.67
EPS (TTM)0.19
Earnings DateN/A
Forward Dividend & Yield0.05 (0.10%)
Ex-Dividend DateDec 10, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ambu A/S: Capital increase in connection with exercise of warrants issued
    GlobeNewswire

    Ambu A/S: Capital increase in connection with exercise of warrants issued

    Capital increase in connection with exercise of warrants Ambu A/S issued 770,000 warrants in 2015 and 419,500 warrants in November 2016. Each warrant entitles the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 46 individuals participate in the 2015 scheme and 71 individuals participate in the 2016 scheme. For both schemes the vesting period is three years, and both schemes can therefore be exercised in the trading window that opened on 27 January 2021 in connection with Ambu’s interim financial report for Q1 2020/21. Since 27 January 2021, instructions have been received to exercise warrants as follows: 2015 scheme: 5 individuals have issued instructions to exercise 55,000 warrants at the agreed exercise price of DKK 39.26 per share with a nominal value of DKK 0.50.2016 scheme: 9 individuals have issued instructions to exercise a total of 32,500 warrants at the agreed exercise price of DKK 77.12 per share with a nominal value of DKK 0.50. Today Ambu’s Board of Directors decided to carry out the capital increase relating to the exercised warrants. As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 43,750 from DKK 111,616,966 to DKK 111,660,716 through the issue of 43,750 Class B shares. Following this and in consideration of the employees having left the company, the following warrants remain under the said schemes: 2015 scheme: 45,000 remaining warrants being held by 5 individuals.2016 scheme: 199,500 remaining warrants being held by 33 individuals. The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 10 February 2021 under the ISIN code of Ambu A/S’ existing B shares (DK0060946788). Under section 32 of the Danish Capital Markets Act, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase. Number of shares(nominal value DKK 0.50)Nominal value(DKK)Voting rightsA shares34,320,00017,160,000343,200,000B shares223,321,432111,660,716223,321,432Total257,641,432128,820,716566,521,432 Contact Michael Højgaard, CFO, tel. +45 4030 4349, email: miho@ambu.com Ambu A/SBaltorpbakken 132750 Ballerup, DenmarkTel. +45 7225 2000CVR no.: 63 64 49 19www.ambu.com About AmbuAmbu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring & diagnostics solutions. The manifestations of our efforts have ranged from early innovations like the Ambu® Bag™ resuscitator and the Ambu® BlueSensor™ electrodes to our newest landmark solutions like the Ambu® aScope™ – the world’s first single-use flexible endoscope. Moreover, we continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on the work of doctors, nurses and paramedics. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,000 people in Europe, North America and the Asia Pacific. For more information, please visit ambu.com. Attachment 05022021 Company_Announcement_no. 12 2020_21

  • Registration of share capital increase of 4,711,832 new B shares completed
    GlobeNewswire

    Registration of share capital increase of 4,711,832 new B shares completed

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. Registration of share capital increase of 4,711,832 new B shares completed Ambu A/S (“Ambu” or the “Company”) has in connection with its accelerated bookbuild offering today registered with the Danish Business Authority the capital increase of a nominal value of DKK 2,355,916 (4,711,832 B shares of DKK 0.50 each) (the “New B Shares”), representing 1.86% of the registered share capital prior to the capital increase. Attachment Company announcement no. 11 2020_21

  • Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
    GlobeNewswire

    Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities

    In accordance with its long-term incentive program ("LTIP") Ambu A/S has allocated performance share units (PSUs) to members of the Executive Board. Reference is made to the company announcement of 29 January 2021 regarding the implementation of the program and the first allocations. Pursuant to the Market Abuse Regulation article 19, Ambu A/S hereby notifies receipt of information of the following transactions in Ambu's shares by persons discharging managerial responsibilities in Ambu A/S. 1.Details of the person discharging managerial responsibilities/person closely associateda)NameMichael Højgaard Abrahamsen2.Reason for the notificationa)Position/statusCFOb)Initial notifica- tion/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc-tion monitora)NameAmbu A/Sb)LEI5299008W2A69WX3557104.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instru- ment Identification codePerformance Share Units linked to shares in Ambu A/S DK0060946788b)Nature of the transactionAllocation of Performance Share Units according to Long-Term Incentive Program.c)Price(s) and volume(s) Price(s)Volume(s)DKK 07,254 PSUs d)Aggregated information Aggregated volumePrice N/A N/A e)Date of the transaction29 January 2021f)Place of the transactionOutside a trading venue Attachment 29_01_2020 Michael Højgaard PSU